Vaxart Inc Net Income
| VXRT Stock | USD 0.57 0.01 1.79% |
As of the 14th of February 2026, Vaxart has the Semi Deviation of 5.9, coefficient of variation of 951.66, and Risk Adjusted Performance of 0.0938. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaxart Inc, as well as the relationship between them.
Vaxart Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.825 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -60.3 M | -57.2 M | |
| Net Loss | -60.3 M | -57.2 M | |
| Net Loss | -97 M | -92.1 M | |
| Net Loss | (0.16) | (0.17) | |
| Net Income Per E B T | 0.90 | 0.62 |
Vaxart | Net Income | Build AI portfolio with Vaxart Stock |
The evolution of Net Income for Vaxart Inc provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vaxart compares to historical norms and industry peers.
Latest Vaxart's Net Income Growth Pattern
Below is the plot of the Net Income of Vaxart Inc over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Vaxart Inc financial statement analysis. It represents the amount of money remaining after all of Vaxart Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Vaxart's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (66.95 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Vaxart Net Income Regression Statistics
| Arithmetic Mean | (35,476,338) | |
| Geometric Mean | 21,241,521 | |
| Coefficient Of Variation | (90.64) | |
| Mean Deviation | 27,326,672 | |
| Median | (19,100,000) | |
| Standard Deviation | 32,156,079 | |
| Sample Variance | 1034T | |
| Range | 108.8M | |
| R-Value | (0.82) | |
| Mean Square Error | 358.7T | |
| R-Squared | 0.67 | |
| Significance | 0.000053 | |
| Slope | (5,231,029) | |
| Total Sum of Squares | 16544.2T |
Vaxart Net Income History
Other Fundumenentals of Vaxart Inc
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Vaxart Net Income component correlations
Vaxart Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Vaxart is extremely important. It helps to project a fair market value of Vaxart Stock properly, considering its historical fundamentals such as Net Income. Since Vaxart's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vaxart's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vaxart's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Vaxart introduce new products? Factors like these will boost the valuation of Vaxart. If investors know Vaxart will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Vaxart listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth 13.679 | Return On Assets | Return On Equity |
Understanding Vaxart Inc requires distinguishing between market price and book value, where the latter reflects Vaxart's accounting equity. The concept of intrinsic value - what Vaxart's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Vaxart's price substantially above or below its fundamental value.
Please note, there is a significant difference between Vaxart's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaxart is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vaxart's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Vaxart 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vaxart's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vaxart.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Vaxart on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Vaxart Inc or generate 0.0% return on investment in Vaxart over 90 days. Vaxart is related to or competes with Acrivon Therapeutics, Unicycive Therapeutics, CAMP4 THERAPEUTICS, Immunic, Pmv Pharmaceuticals, Relmada Therapeutics, and Cibus Global. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant prote... More
Vaxart Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vaxart's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vaxart Inc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.65 | |||
| Information Ratio | 0.0966 | |||
| Maximum Drawdown | 75.42 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 14.29 |
Vaxart Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaxart's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vaxart's standard deviation. In reality, there are many statistical measures that can use Vaxart historical prices to predict the future Vaxart's volatility.| Risk Adjusted Performance | 0.0938 | |||
| Jensen Alpha | 0.802 | |||
| Total Risk Alpha | 0.2439 | |||
| Sortino Ratio | 0.1041 | |||
| Treynor Ratio | 0.9477 |
Vaxart February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0938 | |||
| Market Risk Adjusted Performance | 0.9577 | |||
| Mean Deviation | 4.56 | |||
| Semi Deviation | 5.9 | |||
| Downside Deviation | 7.65 | |||
| Coefficient Of Variation | 951.66 | |||
| Standard Deviation | 8.24 | |||
| Variance | 67.94 | |||
| Information Ratio | 0.0966 | |||
| Jensen Alpha | 0.802 | |||
| Total Risk Alpha | 0.2439 | |||
| Sortino Ratio | 0.1041 | |||
| Treynor Ratio | 0.9477 | |||
| Maximum Drawdown | 75.42 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 14.29 | |||
| Downside Variance | 58.47 | |||
| Semi Variance | 34.77 | |||
| Expected Short fall | (7.14) | |||
| Skewness | 1.08 | |||
| Kurtosis | 13.08 |
Vaxart Inc Backtested Returns
Vaxart appears to be abnormally volatile, given 3 months investment horizon. Vaxart Inc owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.12, which indicates the firm had a 0.12 % return per unit of risk over the last 3 months. By inspecting Vaxart's technical indicators, you can evaluate if the expected return of 0.96% is justified by implied risk. Please review Vaxart's Risk Adjusted Performance of 0.0938, coefficient of variation of 951.66, and Semi Deviation of 5.9 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Vaxart holds a performance score of 9. The entity has a beta of 0.9, which indicates possible diversification benefits within a given portfolio. Vaxart returns are very sensitive to returns on the market. As the market goes up or down, Vaxart is expected to follow. Please check Vaxart's maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to make a quick decision on whether Vaxart's existing price patterns will revert.
Auto-correlation | -0.51 |
Good reverse predictability
Vaxart Inc has good reverse predictability. Overlapping area represents the amount of predictability between Vaxart time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vaxart Inc price movement. The serial correlation of -0.51 indicates that about 51.0% of current Vaxart price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.51 | |
| Spearman Rank Test | -0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Vaxart Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Vaxart Inc reported net income of (66.95 Million). This is 119.62% lower than that of the Biotechnology sector and 195.58% lower than that of the Health Care industry. The net income for all United States stocks is 111.73% higher than that of the company.
Vaxart Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxart's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxart could also be used in its relative valuation, which is a method of valuing Vaxart by comparing valuation metrics of similar companies.Vaxart is currently under evaluation in net income category among its peers.
Vaxart Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vaxart from analyzing Vaxart's financial statements. These drivers represent accounts that assess Vaxart's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vaxart's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.1B | 467.8M | 279.1M | 322.6M | 290.4M | 275.8M | |
| Enterprise Value | 2.9B | 451.2M | 270.9M | 320.7M | 288.6M | 274.2M |
Vaxart Institutional Holders
Institutional Holdings refers to the ownership stake in Vaxart that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Vaxart's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vaxart's value.| Shares | Royal Bank Of Canada | 2025-06-30 | 223.9 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 181 K | Hrt Financial Llc | 2025-06-30 | 178.9 K | Charles Schwab Investment Management Inc | 2025-06-30 | 153.8 K | Virtu Financial Llc | 2025-06-30 | 146.7 K | Amvescap Plc. | 2025-06-30 | 118.7 K | Two Sigma Securities, Llc | 2025-06-30 | 107.8 K | Two Sigma Investments Llc | 2025-06-30 | 106.9 K | Goldman Sachs Group Inc | 2025-06-30 | 97.4 K | Vanguard Group Inc | 2025-06-30 | 10.4 M | Geode Capital Management, Llc | 2025-06-30 | 2.3 M |
Vaxart Fundamentals
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 122.27 M | ||||
| Shares Outstanding | 240.06 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 0.96 % | ||||
| Number Of Shares Shorted | 21.17 M | ||||
| Price To Book | 5.07 X | ||||
| Price To Sales | 0.92 X | ||||
| Revenue | 28.7 M | ||||
| Gross Profit | (30.88 M) | ||||
| EBITDA | (54.87 M) | ||||
| Net Income | (66.95 M) | ||||
| Cash And Equivalents | 129.55 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 23.28 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 8.65 X | ||||
| Book Value Per Share | 0.12 X | ||||
| Cash Flow From Operations | (44.76 M) | ||||
| Short Ratio | 2.61 X | ||||
| Earnings Per Share | (0.22) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 105 | ||||
| Beta | 1.25 | ||||
| Market Capitalization | 135.87 M | ||||
| Total Asset | 166.39 M | ||||
| Retained Earnings | (476.52 M) | ||||
| Working Capital | (22.62 M) | ||||
| Net Asset | 166.39 M |
About Vaxart Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaxart Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxart using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxart Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.